@article{3169530,
    title = "Allergen immunotherapy for allergic rhinoconjunctivitis: protocol for a
systematic review",
    author = "Dhami, Sangeeta and Nurmatov, Ulugbek and Roberts, Graham and Pfaar, and Oliver and Muraro, Antonella and Ansotegui, Ignacio J. and Calderon, and Moises and Cingi, Cemal and Demoly, Pascal and Durham, Stephen and van and Wijk, Ronald Gerth and Halken, Susanne and Hamelmann, Eckard and and Hellings, Peter and Jacobsen, Lars and Knol, Edward and Larenas and Linnemann, Desiree and Lin, Sandra and Maggina, Vivian and and Oude-Elberink, Hanneke and Pajno, Giovanni and Panwankar, Ruby and and Pastorello, Elideanna and Pitsios, Constantinos and Rotiroti, Giuseppina and and Timmermans, Frans and Tsilochristou, Olympia and Varga, Eva-Maria and and Wilkinson, Jamie and Williams, Andrew and Worm, Margitta and Zhang, and Luo and Sheikh, Aziz",
    journal = "Clinical and Translational Allergy",
    year = "2016",
    volume = "6",
    publisher = "BMC",
    doi = "10.1186/s13601-016-0099-6",
    keywords = "Allergy; Allergic rhinoconjunctivitis; Allergen immunotherapy; Rhinitis",
    abstract = "Background: The European Academy of Allergy and Clinical Immunology
(EAACI) is in the process of developing the EAACI Guidelines for
Allergen Immunotherapy (AIT) for the Management of Allergic
Rhinoconjunctivitis. We seek to critically assess the effectiveness,
cost-effectiveness and safety of AIT in the management of allergic
rhinoconjunctivitis.
Methods: We will undertake a systematic review, which will involve
searching international biomedical databases for published, in progress
and unpublished evidence. Studies will be independently screened against
pre- defined eligibility criteria and critically appraised using
established instruments. Data will be descriptively and, if possible and
appropriate, quantitatively synthesised.
Conclusion: The findings from this review will be used to inform the
development of recommendations for EAACI's Guidelines on AIT."
}